Drug intelligence / Profile preview

METGBL

Development stage: Preclinical
Lead developer: Sathgen Therapeutics
Modality: Small Molecules

Overview

METGBL is a preclinical-stage small molecule therapeutic candidate being developed by Sathgen Therapeutics, a subsidiary of Godavari Biorefineries Ltd (GBL). The drug is currently undergoing toxicity and anti-cancer testing. While specific structural details are not publicly disclosed, the identifier likely refers to a metformin-based asset (MET) associated with Godavari Biorefineries (GBL), which is a major manufacturer of metformin. The program focuses on exploring the anti-neoplastic potential of the compound, potentially targeting cancer stem cells or metabolic pathways involved in tumor progression.

Targets

DNA

Beyond the preview

Go deeper on METGBL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METGBL.

Explore the full profile